- Symrise’s forecast for full-year organic sales growth is set at 7%, which is aligned with their prior target range of 5% to 7%, but below the market estimate of 9.18%.
- The company’s sales for the first nine months reached EUR 3.82 billion, with organic sales growth at 11.1%.
- Both business segments, namely Taste, Nutrition & Health and Scent & Care, experienced double-digit growth.
- Symrise maintains its long-term expectation for organic growth between 5% and 7% annually.
- The company has projected its long-term EBITDA margin to remain stable between 20% to 23%.
- In terms of analyst recommendations, Symrise has received 13 buy ratings, 10 hold ratings, and 2 sell ratings.
A look at Symrise AG Smart Scores
Factor | Score | Magnitude |
---|---|---|
Value | 2 | |
Dividend | 2 | |
Growth | 4 | |
Resilience | 3 | |
Momentum | 4 | |
OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Symrise AG shows a positive long-term outlook. With a strong score in Growth and Momentum, the company is positioned for potential expansion and market outperformance. This suggests that Symrise AG is likely to experience steady growth and maintain strong market momentum in the future.
Moreover, Symrise AG also demonstrates resilience in the face of challenges, as indicated by its Resilience score. While the Value and Dividend scores are moderate, the company’s strengths in Growth, Resilience, and Momentum bode well for its overall performance in the long term. Overall, Symrise AG‘s diversified product offerings and customer base position it favorably for continued success in the industry.
Summary: Symrise AG is a diversified chemical manufacturer that produces a wide range of products such as perfume oils, fragrance bases, cosmetic raw materials, and flavorings. The company’s customer base includes manufacturers of fragrances, cosmetics, beverages, and pharmaceuticals, showcasing its broad presence across various industries.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
π‘ Before itβs here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- β Unlimited Research Summaries
- β Personalised Alerts
- β Custom Watchlists
- β Company Analytics and News
- β Events & Webinars